{"id":"NCT01966003","sponsor":"Amgen","briefTitle":"Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer","officialTitle":"A Randomized, Double-blind, Phase 3 Study Evaluating the Efficacy and Safety of ABP 215 Compared With Bevacizumab in Subjects With Advanced Non-Small Cell Lung Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-11-11","primaryCompletion":"2015-07-23","completion":"2015-07-23","firstPosted":"2013-10-21","resultsPosted":"2017-10-19","lastUpdate":"2017-10-19"},"enrollment":642,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Non-small Cell Lung Cancer Metastatic"],"interventions":[{"type":"DRUG","name":"Carboplatin","otherNames":["Paraplatin"]},{"type":"DRUG","name":"Paclitaxel","otherNames":["Taxol"]},{"type":"DRUG","name":"ABP 215","otherNames":[]},{"type":"DRUG","name":"Bevacizumab","otherNames":["Avastin"]}],"arms":[{"label":"ABP 215","type":"EXPERIMENTAL"},{"label":"Bevacizumab","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this research study is to compare the effectiveness and safety of ABP 215 against bevacizumab in men and women with advanced non-small cell lung cancer.","primaryOutcome":{"measure":"Percentage of Participants With an Objective Response","timeFrame":"Disease assessments were performed at weeks 1, 7, 13, 19, and approximately every 9 weeks thereafter. The mean actual follow-up time from randomization was 4.7 and 5.0 months for ABP 215 and bevacizumab, respectively.","effectByArm":[{"arm":"ABP 215","deltaMin":39,"sd":null},{"arm":"Bevacizumab","deltaMin":41.7,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":11},"locations":{"siteCount":4,"countries":["United States","Australia","Bulgaria"]},"refs":{"pmids":["30617139"],"seeAlso":["http://www.amgentrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":85,"n":324},"commonTop":["Alopecia","Nausea","Anaemia","Fatigue","Neutropenia"]}}